NEW YORK (GenomeWeb) – Chinese firms Shuwen Biotech and Jiangsu Hengrui Medicine today announced a collaboration to develop companion diagnostics.

Under the term of the agreement, Shuwen will develop assays and kits for an unidentified anticancer drug candidate that Hengrui is currently developing. Shuwen will also screen patients with the tests at its diagnostic reference laboratories for upcoming clinical trials, as well as manufacture and market the diagnostic if it receives regulatory approval.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.